177748-22-0

Usage

Uses

Used in Pharmaceutical Research:
(E)-4-Hydroxy ToreMifene is used as a research compound for understanding the differences in activity and properties between the (E)and (Z)-isomers of 4-Hydroxy Toremifene. This knowledge can be crucial in the development of new drugs with improved efficacy and reduced side effects.
Used in Quality Control and Standardization:
In the pharmaceutical industry, (E)-4-Hydroxy ToreMifene is used as a reference material for quality control and standardization purposes. It helps ensure the purity and consistency of the active compound, 4-Hydroxy Toremifene, in the final drug product.
Used in Analytical Chemistry:
(E)-4-Hydroxy ToreMifene can be employed as an analytical standard in various chromatographic and spectroscopic techniques. This application aids in the accurate identification and quantification of the compound in pharmaceutical formulations and biological samples.
Used in Drug Metabolism Studies:
As the inactive isomer of 4-Hydroxy Toremifene, (E)-4-Hydroxy ToreMifene can be used in drug metabolism studies to investigate the metabolic pathways and enzyme interactions of the active compound. This information is valuable for understanding the pharmacokinetics and pharmacodynamics of the drug, as well as for designing prodrugs or optimizing drug delivery systems.
Used in Toxicology and Safety Assessment:
(E)-4-Hydroxy ToreMifene can be utilized in toxicology and safety assessment studies to evaluate the potential toxic effects of the compound and its metabolites. This information is essential for determining the safety profile of the drug and establishing appropriate dosages and administration routes.

Upstream product

• 177748-20-8 2,2-Dimethyl-propionic acid 4-{(E)-4-chloro-1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester 
• 611-99-4 4,4'-Dihydroxybenzophenone 
• 107-99-3 2-(dimethylamino)ethyl chloride 
• 936-59-4 3-chloropropiophenone 
• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 
• 177748-18-4 2,2-Dimethyl-propionic acid 4-[(E)-4-chloro-1-(4-hydroxy-phenyl)-2-phenyl-but-1-enyl]-phenyl ester 
• 173163-13-8 4-<2-(N,N-dimethylamino)ethoxy>-4'-hydroxybenzophenone 
• 124-40-3 dimethyl amine 
• 114031-67-3 [4-(4-hydroxybenzoyl)phenyl]-2,2-dimethyl propanoate 

Relevant academic research and scientific papers

New approach based on immunochemical techniques for monitoring of selective estrogen receptor modulators (SERMs) in human urine

Antiestrogenic compounds such as tamoxifen, toremifen and chlomifen are used illegally by athletes to minimize physical impacts such as gynecomastia resulting from the secondary effects of anabolic androgenic steroids, used to increase athletic efficiency unlawfully. The use of these compounds is banned by the World Anti-Doping Agency (WADA) and controls are made through analytical methodologies such as HPLC–MS/MS, which do not fulfil the sample throughput requirements. Moreover, compounds such as tamoxifen are also used to treat hormone receptor-positive breast cancer (ER +).Therapeutic drug monitoring (TDM) of tamoxifen may also be clinically useful for guiding treatment decisions. An accurate determination of these drugs requires a solid phase extraction of patient serum followed by HPLC–MS/MS. In the context of an unmet need of high-throughput screening (HTS) and quantitative methods for antiestrogenic substances we have approached the development of antibodies and an immunochemical assay for the determination of these antiestrogenic compounds. The strategy applied has taken into consideration that these drugs are metabolized and excreted in urine as the corresponding 4-hydroxylated compounds. A microplate-based ELISA procedure has been developed for the analysis of these metabolites in urine with a LOD of 0.15, 0.16 and 0.63 μg/L for 4OH-tamoxifen, 4OH-toremifen and 4OH-clomifen, respectively, much lower than the MRPL established by WADA (20 μg/L).

Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ

Estrogen-related receptors (ERRs, α, β, and γ) are orphan nuclear receptors most closely related in sequence to estrogen receptors (ERα and ERβ). Much attention has been paid recently to the functions of ERRs for their potential roles as new therapeutic t

USE OF A 4-HYDROXYTOREMIFENE PRODRUG FOR TREATMENT OF BREAST CANCER

The present invention is directed to compounds, compositions thereof, and the use of the compounds and compositions for the treatment and prevention of breast cancer. In one embodiment, the present invention relates to the use of a prodrug of endoxifen or

Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRγ

The design and synthesis of 4-hydroxytamoxifen (4-OHT) derivatives are described. The binding affinities of these compounds toward the orphan estrogen-related receptor γ and the classical estrogen receptor α demonstrate that analogs bearing hydroxyalkyl g

Antioxidant compounds

A new use of halogenated triphenylethylene derivatives for lowering levels of serum lipid perioxides and for the prevention or treatment of oxidative tissue damage induced by lipid peroxidation is disclosed. The new use includes the prevention or treatment of atherosclerosis, ischemic injury, psoriasis, inflammatory diseases, such as inflammatory bowel disease, or cardiovascular disorders, such as coronary heart disease, cardiac ischemic injury and post-ischemic cardiac arrhythmias, or the treatment of AIDS.